Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 1.01, 2.03, 3.02, 9.01 · 8-K

CV Sciences, Inc.

CVSIOTCEQUITYCurrent

Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities

Item 1.01 Entry into a Material Definitive Agreement As previously disclosed, on February 12, 2025, CV Sciences, Inc., a Delaware corporation (the “Company”) entered into a note purchase agreement (the “Original Purchase Agreement”) with an institutional investor (“Investor”), pursuant to which the Company issued and sold to the Investor a secured promissory note in the original principal amount o…

Filed Mar 10, 2026Accepted Mar 10, 2026, 5:16 PM EDTCIK 1510964Accession 0001193125-26-100436
Share

Company context

CV Sciences, Inc. (OTCQB:CVSI) is a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products. The Company's products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, +PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces non-cannabinoid supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ brand provides a variety of 100% plant-based food products that are distributed primarily in the EU and other select markets. Cultured Foods™ caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for

Current securities

Historical securities (1)

Recent company filings

  1. 10-Q filingNov 13, 2026
  2. Results of Operations and Financial Condition · Regulation FD DisclosureNov 12, 2026
  3. Other EventsOct 26, 2026
  4. 4 filingSep 9, 2026
  5. 3 filingSep 9, 2026

Disclosure sections

Items 1.01, 2.03, 3.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement As previously disclosed, on February 12, 2025, CV Sciences, Inc., a Delaware corporation (the “Company”) entered into a note purchase agreement (the “Original Purchase Agreement”) with an institutional investor (“Investor”), pursuant to which the Company issued and sold to the Investor a secured promissory note in the original principal amount of $1,600,000 (the “Original Note”). The Original Purchase Agreement and Original Note was amended on September 12, 2025 (the “Amended Original Purchase Agreement” and “Amended Original Note”, respectively). Also as previously disclosed, on October 6, 2025, the Company entered into a note purchase agreement (the “Second Purchase Agreement” and, together with the Amended Original Purchase Agreement, the “Purchase Agreement”) with the Investor, pursuant to which the Company issued and sold to the Investor a second secured promissory note in the original principal amount of $600,000 (the “Second Note” and, together with the Amended Original Note, the “Notes”). On March 4, 2026, the Company and the Investor entered into an agreement (the “Agreement”) to, among other things, amend and restate the Amended Original Note and the Second Note (collectively, the “Amended Notes”). The principal terms of the Agreement and the Amended Notes are as follows: • Conversion Feature. The Amended Notes were amended to add a conversion feature permitting the Investor, at its option, to convert the outstanding principal amount of the Amended Notes into shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at a fixed conversion price of $0.06 per share. The Amended Notes are initially convertible into 37,600,000 shares of Common Stock, subject to increase through the true-up mechanism disclosed below. The Amended Notes are subject to a beneficial ownership limitation of 4.99% of the outstanding shares of Common Stock. The beneficial ownership limitation prevents the Investor from converting any portion of the Amended Notes if, after giving effect to such conversion, the Investor would beneficially own more than 4.99% of the outstanding shares of Common Stock. The Investor may increase the beneficial ownership limitation up to 9.99% upon at least 61 days' prior notice to the Company. • Elimination of Monthly Redemption. The Company’s obligation to redeem a portion of the Notes on a monthly basis prior to maturity has been eliminated in the Amended Notes. • Principal Amounts. The outstanding principal amounts of the Amended Notes were increased by 20% under the terms of the Notes. After such adjustment, the Amended Notes have an aggregate outstanding principal amount of $2,256,000. • True-Up Provision. The Amended Notes include a true-up provision designed to ensure that the net proceeds received by the Investor upon conversion and sale of the conversion shares equals the principal amount of the Amended Notes being converted. If, after the sale of the conversion shares received upon a conversion, the Investor receives net proceeds (net of brokerage, legal opinion fees, and transfer agent fees) of less than 100% of the principal amount of the Amended Notes converted, and the aggregate shortfall under both Amended Notes exceeds $94,000, the Company will issue a new senior secured convertible note on substantially the same terms and conditions of the Amended Notes (the “Third Note”) with a principal amount equal to the aggregate shortfall in excess of $94,000. If issued, the Third Note will be due April 6, 2027. There is no stated maximum number of shares of Common Stock that may be issuable in respect of conversions pursuant to the Third Note. • Documentation Fee. In connection with the Agreement, the Company paid $15,000 to the Investor to cover documentation fees. The preceding descriptions of the Amended Notes and the Agreement do not purport to be complete and are qualified in their entirety by the full text of the Amended Notes and the Agreement of which are filed as exhibits to this report and are incorporated by reference herein.
Item 2.03Item 2.03 - Creation of Direct Financial Obligation
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
Item 3.02Item 3.02 - Unregistered Sales of Equity
Item 3.02 Unregistered Sales of Equity Securities The information set forth under Item 1.01 of this Current Report on Form 8-K regarding the amendment of the Notes to add a conversion feature, and the potential issuance of the Third Note, is incorporated herein by reference in response to this Item 3.02. The securities described therein have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and were issued in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder.
Filed exhibits (1)
EX-99.1 (by filename) cvsi-ex99_1.htm

EX-99.1 6 cvsi-ex99_1.htm EX-99.1 EX-99.1 March 10, 2026 CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in proven, science-backed natural ingredients and products, today announced that it has modified its existing outstanding notes to include a conversion feature pursuant to which the outstanding balance of the notes may be converted into common shares of the Company at a fixed conversion price of $0.06 per share. "We are pleased with the successful completion of a comprehensive debt restructuring, marking a significant milestone in the Company's strategic plan to enhance financial flexibility and accelerate long-term growth." said Joseph Dowling, CEO of CV Sciences. "This is a transformative step for our Company in strengthening our balance sheet and positioning the Company for sustained profitability. This transaction better equips us to deliver value to our customers, partners and shareholders, while pursuing new oppor…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.